Medicxi Ventures Management (Jersey) LTD Phathom Pharmaceuticals, Inc. Transaction History
Medicxi Ventures Management (Jersey) LTD
- $387 Million
- Q1 2025
A detailed history of Medicxi Ventures Management (Jersey) LTD transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Medicxi Ventures Management (Jersey) LTD holds 7,464,572 shares of PHAT stock, worth $32.3 Million. This represents 12.73% of its overall portfolio holdings.
Number of Shares
7,464,572
Previous 7,464,572
-0.0%
Holding current value
$32.3 Million
Previous $60.6 Million
18.72%
% of portfolio
12.73%
Previous 13.31%
Shares
5 transactions
Others Institutions Holding PHAT
# of Institutions
152Shares Held
66.6MCall Options Held
94KPut Options Held
55.5K-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.1MShares$43.8 Million3.99% of portfolio
-
Jennison Associates LLC7.04MShares$30.5 Million0.03% of portfolio
-
Invesco Ltd. Atlanta, GA3.65MShares$15.8 Million0.0% of portfolio
-
Carlyle Group Inc. Washington, DC3.5MShares$15.1 Million27.15% of portfolio
-
Black Rock Inc. New York, NY2.93MShares$12.7 Million0.0% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $170M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...